spawns/E+ via Getty Images A Vaccine Company With a Q1 Earnings Beat After it beat Q1 earnings estimates by an impressive $0.31, Novavax ( NVAX ) gets initial coverage from me today in the biotech/pharma sector, whose profile describes it as a company that "engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, ...
spawns/E+ via Getty Images A Vaccine Company With a Q1 Earnings Beat After it beat Q1 earnings estimates by an impressive $0.31, Novavax ( NVAX ) gets initial coverage from me today in the biotech/pharma sector, whose profile describes it as a company that "engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally." This article will explore 7 rating categories across fundamental and technical analysis, and now is a very relevant time to talk about the vaccine sector again, as mainstream media like NBC News reported on May 8th that "the hantavirus outbreak on the MV Hondius cruise ship brings a new focus to efforts to develop a vaccine to prevent the virus," so I expect a greater focus will emerge in the near term on this industry overall. An Overwhelmingly Neutral Thesis For my initial rating of Novavax, I am taking a neutral view, giving it a hold, which agrees with the latest quant rating and SA analyst consensus as of this writing. NVAX - rating worksheet (author) As you can see from my rating worksheet above, although some more bullish factors included valuation vs upside potential, as well as some performance metrics vs peers, the rest of the thesis is overwhelmingly neutral, as this continues to be a relatively unprofitable company with negative equity but one playing a key role in the vaccine space via collaborations with larger pharma names. The Growth Case Presents a Mixed Bag In this first topic of what could drive growth, I gave the stock a hold, because although there are some interesting potential tailwinds in its pipeline, it also is in a niche that seems highly impacted by seasonal revenue/demand swings. When thinking about what macroeconomic factors could impact growth at Novavax and its sector, it is worth glancing at its portfolio and pipeline of work, showing 2 available vaccines (for Covid-19 and malaria) in collaboration with larger pharma pa...
Encore Capital Group ( ECPG ) priced upsized 6.625% senior secured notes of $750M principal amount due 2032, upsized from $550M, at an issue price of 100.00% in a private offering. The company plans to use the proceeds, along with revolving credit facility borrowings, to fully redeem its $500M 9.25% senior secured notes due 2029, partially redeem €200M of its €415M floating rate notes due 2028, an...
Encore Capital Group ( ECPG ) priced upsized 6.625% senior secured notes of $750M principal amount due 2032, upsized from $550M, at an issue price of 100.00% in a private offering. The company plans to use the proceeds, along with revolving credit facility borrowings, to fully redeem its $500M 9.25% senior secured notes due 2029, partially redeem €200M of its €415M floating rate notes due 2028, and cover related fees, expenses, and underwriting discounts. The transaction does not change its FY2026 guidance provided on May 6, 2026. More on Encore Capital Encore Capital Group, Inc. 2026 Q1 - Results - Earnings Call Presentation Encore Capital Group, Inc. (ECPG) Q1 2026 Earnings Call Transcript Encore Capital Group, Inc. (ECPG) Presents at 47th Annual Raymond James Institutional Investor Conference - Slideshow Encore Capital plans to raise $550M in senior secured notes offering Encore Capital GAAP EPS of $3.86 beats by $0.85, revenue of $475.41M beats by $29.15M
Daiichi Sankyo says its underlying business remains strong despite a one‑time expense and conservative earnings guidance that came in below market expectations. The Japanese drugmaker reported double‑digit growth and rising revenue, supported by robust demand for its flagship cancer treatments. The company also outlined its medium‑term outlook, highlighting antibody‑drug conjugates, research inves...
Daiichi Sankyo says its underlying business remains strong despite a one‑time expense and conservative earnings guidance that came in below market expectations. The Japanese drugmaker reported double‑digit growth and rising revenue, supported by robust demand for its flagship cancer treatments. The company also outlined its medium‑term outlook, highlighting antibody‑drug conjugates, research investment and the role of artificial intelligence, even as competition intensifies and currency moves remain a factor. Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo, spoke exclusively with Shery Ahn on Insight with Haslinda Amin about results, strategy and growth priorities. (Source: Bloomberg)
In this article ENRN-FF ENRN-FF 0P6S-GB 0P6S-GB IMB-GB UN0-DE Follow your favorite stocks CREATE FREE ACCOUNT An employee of Basra Oil Company, works at the Nahr Bin Umar Oil and Gas Field on the outskirts of the southern Iraqi city of Basra on April 29, 2026. Hussein Faleh | Afp | Getty Images LONDON — European stocks are expected to open in negative territory as prospects for a speedy resolution...
In this article ENRN-FF ENRN-FF 0P6S-GB 0P6S-GB IMB-GB UN0-DE Follow your favorite stocks CREATE FREE ACCOUNT An employee of Basra Oil Company, works at the Nahr Bin Umar Oil and Gas Field on the outskirts of the southern Iraqi city of Basra on April 29, 2026. Hussein Faleh | Afp | Getty Images LONDON — European stocks are expected to open in negative territory as prospects for a speedy resolution to the U.S.-Iran war appear increasingly remote. The U.K.'s FTSE 100 index is seen opening 0.5% lower, with Germany's DAX down 0.76%, France's CAC 40 down 0.4% and Italy's FTSE MIB 0.56% lower, according to data from IG. Optimism over a looming U.S.-Iran peace agreement was dealt a reality check late on Monday when President Donald Trump said the ongoing ceasefire is "on life support" after Tehran sent an " unacceptable " counter to Washington's proposal to end the war. The state of the month-old truce is "unbelievably weak," Trump told reporters in the Oval Office. Oil prices rose in response to the comments and, overnight, bourses in the Asia-Pacific region traded in mixed territory . Meanwhile, U.S. stock futures hovered near the flatline on Monday night as traders looked ahead to the release of April's consumer price index reading . Economists polled by Dow Jones expect inflation to have gained 3.7% from a year earlier. A growing political crisis in the U.K. is also in focus for European markets on Tuesday as over 70 Labour Party lawmakers, including government ministers, have now called on Prime Minister Keir Starmer to resign or set out a timetable for his resignation. It comes after the ruling party's dire performance in local council elections last week. The prime minister took responsibility for the poor election results and acknowledged on Monday that he had "doubters" . Starmer pledged to "face up to the big challenges" facing the country, but the speech failed to impress party insiders as several ministerial aides quit on Monday. Earnings reports come from Siem...
matejmo/iStock via Getty Images Quarterly commentary Financial assets experienced mixed returns in the first quarter. The fund posted a negative total return but outperformed the benchmark. Asset allocation and underlying manager performance each contributed positively. Market review and outlook The world financial markets, after performing well in the first two months of the year on continued opt...
matejmo/iStock via Getty Images Quarterly commentary Financial assets experienced mixed returns in the first quarter. The fund posted a negative total return but outperformed the benchmark. Asset allocation and underlying manager performance each contributed positively. Market review and outlook The world financial markets, after performing well in the first two months of the year on continued optimism about trends in economic growth and interest rates, turned lower following the start of the conflict in the Middle East in Iran in early March. The ensuing spike in oil prices, together with concerns about possible shortages of other commodities caused by disrupted supply chains, dampened the growth outlook and led to a sharp rise in inflation expectations. The deteriorating inflation picture, in turn, dashed optimism that central banks could continue cutting rates. In combination, these developments led to a surge in global government bond yields that erased the positive total returns achieved in the first two months of the year. The conflict also fueled a sizable downturn in major global equity indexes in March, sending stocks into the red. With this said, the majority of the negative return for equities stemmed from weakness in the growth style in general, and mega-cap U.S. technology stocks in particular. Conversely, the value style, dividend payers, and more defensive companies generally produced positive returns, benefiting diversified investors. We're encouraged by the broadening of leadership away from the "Magnificent Seven" group of U.S. tech companies, as it provided a tailwind for our diversified positioning. Contributors and detractors Underlying manager performance was the primary contributor to relative performance in the quarter, highlighted by relative strength in international equities. The effect of allocation was roughly neutral. On the positive side, we benefited from having an overweight in U.S. mid-cap stocks and developed-market international e...
Supply Lines is a daily newsletter that tracks global trade. Sign up here . The impact of the energy crisis on the global economy in recent months is showing up in gauges of supply-chain stress that flashed red during the pandemic, adding to reasons for central banks to be on guard for a recurrence of high inflation. The following dashboard of logistics activity shows that some gauges are at their...
Supply Lines is a daily newsletter that tracks global trade. Sign up here . The impact of the energy crisis on the global economy in recent months is showing up in gauges of supply-chain stress that flashed red during the pandemic, adding to reasons for central banks to be on guard for a recurrence of high inflation. The following dashboard of logistics activity shows that some gauges are at their highest since the 2020-23 period, when economies locked down, shortages emerged and shipping snarls persisted. While the indexes are still far from their Covid highs, they reflect disruptions to global trade from the Iran war that bear some similarities to what happened back then. Logistics captures the movement of goods between suppliers, factories and final consumers, and accounts for an estimated 10% of world GDP, showcasing its important role in the global economy. “The closer we get towards actual quantity constraints on key commodities, the more upwards pressure we’re likely to see on prices,” said Shanella Rajanayagam , a trade economist at HSBC Holdings Plc . Earlier on Tuesday, data from the US Bureau of Labor Statistics showed rising costs for gasoline and groceries as the consumer price index advanced by the most since 2023. After adjusting for inflation, wages fell for the first time in three years. Fed Gauge Fresh strains are reflected in the Federal Reserve Bank of New York’s Global Supply Chain Pressure Index . After going quiet for the past three years, it’s risen for three straight months — with an especially pronounced increase in April to the highest level in almost four years. World Bank The World Bank’s Global Supply Chain Stress Index is flirting with its pandemic peak. This measure focuses on fluidity in container shipping and ports, and looks at larger vessels that typically sail long international routes. A contributing factor to the current level for the index is the decision by many cargo carriers — for safety and insurance reasons — to avoid the...
Earnings Call Insights: RadNet (RDNT) Q1 2026 Management View "I'm extremely pleased with the performance of the first quarter." (Chairman, President & CEO Howard Berger) "Revenue and adjusted EBITDA were first quarter records" and were "negatively impacted by an estimated $13 million of revenue and $9 million of adjusted EBITDA from severe weather conditions"; he added that the "strong March perf...
Earnings Call Insights: RadNet (RDNT) Q1 2026 Management View "I'm extremely pleased with the performance of the first quarter." (Chairman, President & CEO Howard Berger) "Revenue and adjusted EBITDA were first quarter records" and were "negatively impacted by an estimated $13 million of revenue and $9 million of adjusted EBITDA from severe weather conditions"; he added that the "strong March performance has continued throughout April and into the first part of May" and said this "drove our confidence to raise 2026 full year guidance for imaging center revenue, adjusted EBITDA and free cash flow." (Chairman, President & CEO Berger) "During the quarter, PET/CT procedures increased 35.2% in aggregate and 14.7% on a same-center basis." (Chairman, President & CEO Berger) He also said "29.3% of our procedural volume was from advanced imaging compared with 26.9% last year's first quarter" and tied utilization gains to DeepHealth tools, noting that "the implementation of TechLive... has significantly benefited RadNet's MRI utilization by substantially decreasing exam room closure hours." (Chairman, President & CEO Berger) "We increased revenue by $30 million at the low and high end of the guidance range, increased adjusted EBITDA by $5 million... and... increased free cash flow by $7 million at the low and high end of the guidance ranges." (Executive VP & CFO Mark Stolper) He also highlighted balance sheet and working-capital execution: "we had $455.3 million of cash" and "lowered DSOs... to a RadNet record low of 29.5 days." (Executive VP & CFO Stolper) "We ended Q1 2026 with $97 million in annual recurring revenue, ARR, representing a 95% year-over-year growth." (President & CEO of Digital Health Cornelis Wesdorp) He said DeepHealth is "on plan to reach our target of more than $140 million in ARR by year-end" and described "$7 million in signed ARR that's fully secured, but not yet reflected in our Q1 ARR" plus "$16 million in total contract value this quarter across 40 ...